Summit Street Capital Management LLC Sells 3,988 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Summit Street Capital Management LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 32,443 shares of the biotechnology company's stock after selling 3,988 shares during the period. United Therapeutics makes up 4.1% of Summit Street Capital Management LLC's holdings, making the stock its 5th largest position. Summit Street Capital Management LLC owned 0.07% of United Therapeutics worth $11,447,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in UTHR. Signaturefd LLC boosted its position in shares of United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after acquiring an additional 30 shares in the last quarter. Parallel Advisors LLC increased its stake in United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 30 shares in the last quarter. Anchor Investment Management LLC increased its stake in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares in the last quarter. Great Lakes Advisors LLC increased its stake in United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its stake in United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after purchasing an additional 33 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley boosted their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target on the stock in a research report on Monday, April 21st. Finally, Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Trading Up 0.0%

Shares of UTHR traded up $0.11 during mid-day trading on Wednesday, hitting $309.68. The company's stock had a trading volume of 321,096 shares, compared to its average volume of 443,747. United Therapeutics Co. has a 52-week low of $264.33 and a 52-week high of $417.82. The company's 50-day moving average is $300.00 and its 200-day moving average is $339.52. The firm has a market capitalization of $13.97 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.17 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. The trade was a 22.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at $10,437,712.18. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,500 shares of company stock worth $17,054,780. 10.30% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.